Anti-malaria drug may also fight Zika virus: study

Image
Press Trust of India New York
Last Updated : Nov 17 2017 | 5:02 PM IST
A drug used to prevent and treat malaria may also be effective against Zika virus, a study has found.
The medication, called chloroquine, has a long history of safe use during pregnancy, and is relatively inexpensive, according to the study published in the journal Scientific Reports.
Zika virus remains a major global health risk. In most adults, Zika causes mild flu-like symptoms.
However in pregnant women, the virus can cause serious birth defects in babies - including microcephaly - a neurological condition in which newborns have unusually small heads and fail to develop properly.
There is no treatment or way to reverse the condition.
"There is still an urgent need to bolster our preparedness and capacity to respond to the next Zika outbreak," said Alexey Terskikh, from the Sanford Burnham Prebys Medical Discovery Institute (SBP) in the US.
"Our latest research suggests the anti-malaria drug chloroquine may be an effective drug to treat and prevent Zika infections," Terskikh said.
The study examined the effect of chloroquine in human brain organoids and pregnant mice infected with the virus, and found the drug markedly reduced the amount of Zika virus in maternal blood and neural progenitor cells in the fetal brain.
Pregnant mice received chloroquine through drinking water in dosages equivalent to acceptable levels used in humans.
"Chloroquine has a long history of successfully treating malaria, and there are no reports of it causing birth defects," said Terskikh.
"Additional studies are certainly needed to determine the precise details of how it works. But given its low cost, availability and safety history further study in a clinical trial to test its effectiveness against Zika virus in humans is merited," Terskikh added.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 17 2017 | 5:02 PM IST

Next Story